Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FPF3400 long-term selenium supplementation study
jRCT2080222756Phase 3Completed
- Sponsor
- Fujimoto Pharmaceutical
- Start
- Feb 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of sodium selenite in selenium deficiency (3 arms), sponsored by Fujimoto Pharmaceutical. Primary endpoints: Maintenance of normal serum selenium concentration and Safety of long-term FPF3400 administration. Started Feb 2015; status: completed.
02
Drugs
sodium selenite
03
Conditions
selenium deficiency
Beyond the preview
Go deeper on jRCT2080222756.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080222756.